798545-30-9 Usage
General Description
6-Bromoquinoline-3-carboxylic Acid is a chemical compound with the molecular formula C10H6BrNO2. Its systematic name is 6-Bromo-1H-quinoline-3-carboxylic acid. It falls under the category of quinolines and belongs to the group of organic compounds. Due to its bromo functional group, it exhibits properties significant to a plethora of biological research and chemical reactions. Though present as a solid, the detailed properties such as density, boiling point, melting point, etc., of this compound can vary significantly depending upon the conditions it is in. As is the case with many organic compounds, caution is necessary in handling this chemical due to its potential reactivity.
Check Digit Verification of cas no
The CAS Registry Mumber 798545-30-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,9,8,5,4 and 5 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 798545-30:
(8*7)+(7*9)+(6*8)+(5*5)+(4*4)+(3*5)+(2*3)+(1*0)=229
229 % 10 = 9
So 798545-30-9 is a valid CAS Registry Number.
InChI:InChI=1/C10H6BrNO2/c11-8-1-2-9-6(4-8)3-7(5-12-9)10(13)14/h1-5H,(H,13,14)
798545-30-9Relevant articles and documents
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
-
, (2016/04/26)
The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.
COMBINATION OF KINASE INHIBITORS AND USES THEREOF
-
, (2014/10/04)
The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.
